{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:59:21Z","timestamp":1774882761546,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":928,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ccr.2011.01.008","type":"journal-article","created":{"date-parts":[[2011,1,20]],"date-time":"2011-01-20T04:32:38Z","timestamp":1295497958000},"page":"11-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":231,"title":["Mutant BRAF Melanomas\u2014Dependence and Resistance"],"prefix":"10.1016","volume":"19","author":[{"given":"Poulikos I.","family":"Poulikakos","sequence":"first","affiliation":[]},{"given":"Neal","family":"Rosen","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ccr.2011.01.008_bib1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2011.01.008_bib2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nsmb.1606","article-title":"PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity","volume":"16","author":"Cameron","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ccr.2011.01.008_bib3","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2001148","article-title":"BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation","volume":"3","author":"Corcoran","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ccr.2011.01.008_bib4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2011.01.008_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.9033","article-title":"AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study","volume":"26","author":"Dummer","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccr.2011.01.008_bib6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccr.2011.01.008_bib7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ccr.2011.01.008_bib8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J.\u00a0Med."},{"key":"10.1016\/j.ccr.2011.01.008_bib9","doi-asserted-by":"crossref","first-page":"8736","DOI":"10.1158\/0008-5472.CAN-10-0902","article-title":"Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells","volume":"70","author":"Gopal","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2011.01.008_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2011.01.008_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ccr.2011.01.008_bib12","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1158\/0008-5472.CAN-08-3563","article-title":"Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase\/mitogen-activated protein kinase pathway suppression","volume":"69","author":"Hoeflich","year":"2009","journal-title":"Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.ccr.2011.01.008_bib13","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1200\/jco.2010.28.15_suppl.2503","article-title":"Safety and efficacy results from the first-in-human study of the oral MEK 1\/2 inhibitor GSK1120212","volume":"28","author":"Infante","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccr.2011.01.008_bib14","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2011.01.008_bib15","doi-asserted-by":"crossref","first-page":"14903","DOI":"10.1073\/pnas.1008990107","article-title":"The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner","volume":"107","author":"Joseph","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"15_suppl","key":"10.1016\/j.ccr.2011.01.008_bib16","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/jco.2010.28.15_suppl.8503","article-title":"Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors","volume":"28","author":"Kefford","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccr.2011.01.008_bib17","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","article-title":"Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma","volume":"68","author":"Montagut","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2011.01.008_bib18","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2011.01.008_bib19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nchembio.183","article-title":"Inhibitor hijacking of Akt activation","volume":"5","author":"Okuzumi","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ccr.2011.01.008_bib20","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy","volume":"102","author":"Paraiso","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ccr.2011.01.008_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2011.01.008_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4065\/83.7.825","article-title":"Malignant melanoma in the 21st century: the emerging molecular landscape","volume":"83","author":"Sekulic","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ccr.2011.01.008_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ccr.2010.05.023","article-title":"4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors","volume":"18","author":"She","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2011.01.008_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ccr.2011.01.008_bib25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccr.2011.01.008_bib26","doi-asserted-by":"crossref","first-page":"35ra41","DOI":"10.1126\/scitranslmed.3000758","article-title":"Gatekeeper mutations mediate resistance to BRAF-targeted therapies","volume":"2","author":"Whittaker","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccr.2011.01.008_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(09)02001-6","article-title":"Ras signaling and therapies","volume":"102","author":"Young","year":"2009","journal-title":"Adv. Cancer Res."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610811000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610811000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:54:53Z","timestamp":1761522893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610811000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1535610811000092"],"URL":"https:\/\/doi.org\/10.1016\/j.ccr.2011.01.008","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutant BRAF Melanomas\u2014Dependence and Resistance","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccr.2011.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}